P
Phathom Pharmaceuticals
Biotech & Life Sciences · Florham Park, United States · Founded 2018 · IPO 2019
Phathom Pharmaceuticals is a biopharmaceutical company MoreLess
Phathom Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for acid-related gastrointestinal disorders. The company primarily serves adult patients suffering from conditions such as Erosive Esophagitis and heartburn. Operating in the healthcare and pharmaceutical market, Phathom Pharmaceuticals leverages its expertise to bring new therapeutic options to patients who need them most. The company's business model revolves around the research, development, and commercialization of prescription medicines, with its flagship product being VOQUEZNA (vonoprazan). This product is designed to heal acid-related damage to the esophagus and provide relief from heartburn. Phathom Pharmaceuticals generates revenue through the sale of its prescription medications, targeting healthcare providers and patients as its primary clients. The company is committed to ethical business practices and compliance with all applicable laws and regulations.
Keywords: biopharmaceutical, gastrointestinal, Erosive Esophagitis, heartburn, VOQUEZNA, vonoprazan, healthcare, innovation, treatment, compliance.
Company overview
Phathom Pharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Florham Park, United States
- Employees
- 433
- Open positions
- 31
- Dealroom signal
- 75.4
Valuation & funding
Phathom Pharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | Aug 2024 | $130M | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | May 2023 | $131M | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Nov 2022 | $40M | — | NovaQuest Capital Management · Sagard · Hercules Capital | ↗ |
| POST IPO DEBT✓Debt | Sep 2021 | $200M | — | Hercules Capital | ↗ |
| IPO✓Exit | Oct 2019 | $0 | — | Undisclosed | — |
| EARLY VCEquity / VC | May 2019 | Frazier Healthcare Partners | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Phathom Pharmaceuticals website traffic
Latest recorded traffic for Phathom Pharmaceuticals is 7.4K monthly website visits, down 22.1% over the last three months. Phathom Pharmaceuticals's team grew 8.8% over the past year.
Hiring
Open positions at Phathom Pharmaceuticals
Current openings linked to this company in Dealroom.
Comparisons
Phathom Pharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 XeratausUsing a new approach toward design, development, and technologies to offer determined innovation for Healthcare Advancements |
Miami, United States | Operational | 1 | $50M | $100M |
 Clairvoyant TherapeuticsProvides evidence-based psychedelic therapy to help patients live healthier and enriched lives |
Vancouver, Canada | Acquired | |||
 OrchidGenetic testing solutions for personalized health risk assessment and family planning |
San Francisco, United States | Operational | |||
 SeriTechInnovative Health and Skin Care |
Barcelona, Spain | Operational | |||
 Mimosa TherapeuticsOffering research-grade natural psilocybin and drug potency test kits |
United States | Operational | |||
 CG OncologyFocused on developing bladder cancer therapeutics |
Irvine, United States | Operational | |||
 AntegenesGenetic tests for personalized cancer risk prevention |
Tartu, Estonia | Operational | |||
 GLX AnalytixBringing personalized medicine to your health care |
Copenhagen, Denmark | Operational |
Talent graph
Phathom Pharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Phathom Pharmaceuticals has talent and traffic
team presence
In the news
Latest news about Phathom Pharmaceuticals
Recent press, funding announcements, and product moves mentioning Phathom Pharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Phathom Pharmaceuticals
An AI-synthesized read of the highest-engagement posts about Phathom Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Phathom Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.